RLMD (44) SPRY (27) CYPH (40) GALT (42) ⌘ Pro Terminal →

Emergent BioSolutions Inc. (EBS) — RQD Stock Rating Cockpit

$7.22 +1.83% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

Emergent BioSolutions Inc. (EBS) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $370.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-2.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EBS)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

5330 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

1.41>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

8 / 99-Pt Accounting

52-WEEK LASER RANGE29% OF RANGE

L: $4$7.22H: $14

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (56% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: CRQD 13 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D+RQD 21 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on EBS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (65)

8.9% ROIC with 56.1% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (45)

Altman-Z 1.41 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (52)

21/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like EBS

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EBS)

✓Walkthrough of EBS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EBS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -12.27%⚡ TESTING RESISTANCE

2026-10-30O $7.11H $7.31L $6.76C $7.22VOL 754.4K

RES: $7.27SUP: $6.17SMA50: $6.47SMA200: $8.01

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EBS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EBS Butterfly Map → + Track EBS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-8.0%/yr Implied 5Y Growth

vs. -28.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EBS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EBS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EBS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EBS)

Health Care Rank #306 of 1016 ⚔️ RLMD vs EBS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EBS vs. RLMD, SPRY, CYPH, GALT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Emergent BioSolutions Inc. (EBS) ranks #306 by composite RQD confidence (53/100, grade D+) and #492 by equity capitalization ($370.2M). Within this direct 5-issuer industry benchmark cohort, EBS leads on earnings valuation at 7.0x trailing P/E, while EBS leads on capital efficiency and profitability with 8.9% ROIC and 56.1% gross margin. EBS currently leads its immediate peer cohort in composite quantitative strength at 53/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EBS ACTIVE Emergent BioSolutions Inc.	D+	53/100	7.0x	56.1%	8.9%	+1.83%	$370.2M	Benchmark Subject
RLMD Relmada Therapeutics Inc.	D	44/100	—	—	-35.0%	+2.69%	$366.9M	/rlmd-vs-ebs →
SPRY ARS Pharmaceuticals Inc.	E	27/100	—	—	-35.0%	+0.27%	$364.0M	/spry-vs-ebs →
CYPH Cypherpunk Technologies Inc.	D-	40/100	71.3x	—	-23.3%	+2.16%	$356.7M	/cyph-vs-ebs →
GALT Galectin Therapeutics Inc.	D-	42/100	—	—	-35.0%	-0.56%	$355.8M	/galt-vs-ebs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001367644

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Emergent BioSolutions Inc. (EBS) reported GAAP revenue of $742.9M (-28.8% vs. FY2024 revenue of $1.04B , and -29.2% cumulative change since FY2023) , GAAP net income of $52.6M, operating cash flow of $170.6M, and free cash flow of $156.8M (+338.0% YoY). On the balance sheet, EBS closed FY2025 with $1.32B in total assets against $572.1M in total debt (Altman Z-Score: 1.41, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$742.9M	$52.6M	$170.6M	$156.8M	$1.32B	$572.1M
FY2024 (FY)	2024-12-31	$1.04B	-$190.6M	$58.7M	$35.8M	$1.39B	$663.7M
FY2023 (FY)	2023-12-31	$1.05B	-$760.5M	-$206.3M	-$206.3M	—	—

3. EBS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EBS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Emergent BioSolutions Inc. (NYSE: EBS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $7.22 (+1.83% 1D, market cap $370.2M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 9/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, EBS ranks #306 in composite RQD confidence.

How does EBS compare to RLMD and SPRY in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EBS carries a Roarable D+ (53/100 RQD), trailing P/E of 7.0x, gross margin of 56.1%, and ROIC of 8.9%. By comparison, RLMD (Relmada Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $366.9M) and SPRY (ARS Pharmaceuticals Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $364.0M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EBS?

Per EBS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001367644), Emergent BioSolutions Inc. generated $742.9M in revenue (-28.8% YoY), $52.6M in net income, and $156.8M in free cash flow against $1.32B in total assets and $572.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EBS trading relative to its 50-day, 200-day, and 52-week technical levels?

EBS last traded at $7.22 (+1.83% on volume of 682,401 shares), positioning the stock +11.59% above its 50-day simple moving average ($6.47) and -9.86% below its 200-day simple moving average ($8.01). Across its 52-week range of $4.36 to $14.06, EBS sits at the 29.5% percentile with a 14-day RSI of 53.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.32 to $8.12).

EBS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell EBS stock right now?

Emergent BioSolutions Inc. (EBS) currently earns a Roarable Rating of D+ (Sell — SELL) with 53/100 RQD Confidence. Stretched risk/reward at 7x P/E (9% return on capital) under elevated 10-year interest-rate pressure.

What is EBS's 12-month price target and RQD AI Jury consensus?

EBS's 12-month base price target is $7.06 (range $5.51 to $14.76), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: EBS RQD Cockpit EBS 12M Forecast EBS Earnings & Move EBS Dividends & DRIP EBS Insiders & 13F EBS Whale Options EBS Profit Sankey EBS News & Why